BCAB

BioAtla, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website bioatla.com
Employees(FY) 66
ISIN US09077B1044

Performance

-32.42%

-23.71%

-22.11%

-47.7%

-39.84%

YTD

-11.38%

Profile

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

Advanced Technical Analysis

Technical Analysis of BCAB 2024-11-20

The stock indicators reflect a bearish sentiment, with the Moving Average Score at 10, Oscillators Score at 36, and a Technical Score of 23, indicating overall weakness in price momentum and suggesting caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of BCAB

Stock Rank

Recent News & Updates

2024-11-08 03:03
BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges(Yahoo Finance)
2024-11-07 03:01
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress(Globenewswire)
2024-10-30 20:00
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024(Globenewswire)
2024-10-20 04:06
BioAtla, Inc. (BCAB): Among Michael Burry's Top 10 Stock Picks Heading Into 2025(Insidermonkey)
2024-10-09 05:57
BioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges(Yahoo Finance)
2024-10-03 21:05
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting(Globenewswire)
2024-09-30 20:00
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress(Globenewswire)
2024-09-22 19:30
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody(Globenewswire)
2024-09-15 20:00
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Soci(Globenewswire)
2024-09-08 20:00
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting(Globenewswire)
2024-08-27 20:00
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-08 04:05
Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress(Yahoo Finance)
2024-07-31 20:00
BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024(Globenewswire)
2024-07-31 01:11
These 2 Strong Buy Penny Stocks Are Poised for a Big Rally, Say Analysts(Yahoo Finance)
2024-07-25 05:39
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day(Globenewswire)
2024-07-24 00:54
BioAtla receives FDA fast track designation for ozuriftamab vedotin(Yahoo Finance)
2024-07-22 20:00
BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(Globenewswire)
2024-06-26 20:00
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024(Globenewswire)
2024-05-28 20:00
BioAtla to Participate in the Jefferies Global Healthcare Conference(Globenewswire)
2024-05-23 05:05
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting(Globenewswire)
2024-05-14 20:18
BioAtla, Inc. (NASDAQ:BCAB) Q1 2024 Earnings Call Transcript(Insidermonkey)
2024-05-14 19:01
BioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights: Strategic Adjustments and ...(Yahoo Finance)
2024-05-14 08:57
BCAB Stock Earnings: BioAtla Beats EPS for Q1 2024(Investorplace)
2024-05-14 04:05
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress(Globenewswire)
2024-05-07 20:00
BioAtla to Participate in the Citizens JMP Life Sciences Conference(Globenewswire)
2024-05-06 20:00
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024(Globenewswire)
2024-05-05 21:14
BioAtla's Multiple Cancer Drug Candidate Receives FDA Clearance(Yahoo Finance)
2024-05-05 20:00
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors(Yahoo Finance)
2024-04-24 04:35
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting(Globenewswire)
2024-03-26 22:07
BioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Call Transcript(Insidermonkey)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.